Adamis gets FDA OK for pre-filled epinephrine syringe
SILVER SPRING, Md. — The Food and Drug Administration last week approved Adamis Pharmaceuticals’ Symjepi, a pre-filled dose syringe of epinephrine. The syringe is indicated for emergency treatment of allergic reactions, including anaphylaxis.
“With an anticipated lower cost, small size and user-friendly design, we believe Symjepi could be an attractive option for a significant portion of both the retail (patient) and non-retail (professional) sectors of the epinephrine market,” Adamis president and CEO Dennis Carlo said. “We are currently in the process of exploring all of our commercialization options and in discussions with potential partners in order to facilitate broad patient access to this new epinephrine treatment option and to maximize the value of our important asset.”
The company said that it’s expecting a launch in the second-half of 2017, and that it has already submitted an application to the FDA for a junior version of Symjepi.
“ We are committed to helping patients by providing them with additional therapeutic choices,” Carlo said.